logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9243002 B1

PDFFull Text
Date of Patent:
Jan. 26, 2016

Filed:

Feb. 03, 2014

Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Xing Dai, Cranford, NJ (US);

Hong Liu, Hillsborough, NJ (US);

Anandan Palani, Bridgewater, NJ (US);

Shuwen He, Fanwood, NJ (US);

Linda L. Brockunier, Orange, NJ (US);

Ravi Nargund, East Brunswick, NJ (US);

Karen Marcantonio, New York, NY (US);

Nicolas Zorn, Durmenach, FR;

Dong Xiao, Warren, NJ (US);

Xuanjia Peng, Shanghai, CN;

Peng Li, Shanghai, CN;

Tao Guo, Shanghai, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Anna L. Cocuzzo

Alysia A. Finnegan

Primary Examiner:

Charanjit Aulakh

Int. Cl.
CPC ...
A61K 31/4375 (2006.01); C07D 471/12 (2006.01); C07D 519/00 (2006.01); A61K 45/06 (2006.01); C07D 471/14 (2006.01); A61K 31/5025 (2006.01); A61K 31/519 (2006.01); A61K 31/55 (2006.01); C07D 471/22 (2006.01); C07D 471/04 (2006.01); C07D 471/20 (2006.01); A61K 31/438 (2006.01);
U.S. Cl.
CPC ...
C07D 519/00 (2013.01); A61K 31/438 (2013.01); A61K 31/4375 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01); C07D 471/14 (2013.01); C07D 471/20 (2013.01); C07D 471/22 (2013.01);
Abstract

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Find Patent Forward Citations

Loading…